VioQuest Pharmaceuticals, Inc. (VOQP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2007 | 8.77 Million USD | 66.23% |
| 2006 | 5.28 Million USD | -63.55% |
| 2005 | 14.49 Million USD | 207.7% |
| 2004 | 4.7 Million USD | 88.18% |
| 2003 | 2.5 Million USD | 1490.26% |
| 2002 | 157.36 Thousand USD | -47.82% |
| 2001 | 301.59 Thousand USD | -5.37% |
| 2000 | 318.71 Thousand USD | 58.1% |
| 1999 | 201.59 Thousand USD | 1.93% |
| 1998 | 197.78 Thousand USD | 9.65% |
| 1997 | 180.37 Thousand USD | -16.3% |
| 1996 | 215.51 Thousand USD | -3.58% |
| 1995 | 223.51 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2008 Q1 | 1.66 Million USD | -0.65% |
| 2008 Q2 | 1.02 Million USD | -38.45% |
| 2007 Q4 | 1.68 Million USD | -37.14% |
| 2007 FY | 8.77 Million USD | 66.23% |
| 2007 Q3 | 2.67 Million USD | 24.72% |
| 2007 Q2 | 2.14 Million USD | -6.1% |
| 2007 Q1 | 2.28 Million USD | 14.14% |
| 2006 Q1 | 2.18 Million USD | -76.84% |
| 2006 FY | 5.28 Million USD | -63.55% |
| 2006 Q4 | 1.99 Million USD | 111.07% |
| 2006 Q3 | 947.37 Thousand USD | -53.88% |
| 2006 Q2 | 2.05 Million USD | -6.19% |
| 2005 Q3 | 1.93 Million USD | 21.13% |
| 2005 FY | 14.49 Million USD | 207.7% |
| 2005 Q2 | 1.59 Million USD | 5.96% |
| 2005 Q1 | 1.5 Million USD | -80.05% |
| 2005 Q4 | 9.45 Million USD | 389.22% |
| 2004 Q1 | 1.04 Million USD | 16.97% |
| 2004 FY | 4.7 Million USD | 88.18% |
| 2004 Q4 | 7.55 Million USD | 672.78% |
| 2004 Q3 | 976.99 Thousand USD | -27.94% |
| 2004 Q2 | 1.35 Million USD | 30.29% |
| 2003 FY | 2.5 Million USD | 1490.26% |
| 2003 Q1 | 395.44 Thousand USD | 932.7% |
| 2003 Q3 | 596.62 Thousand USD | -3.89% |
| 2003 Q2 | 620.77 Thousand USD | 56.98% |
| 2003 Q4 | 889.71 Thousand USD | 49.12% |
| 2002 Q2 | 52.52 Thousand USD | 22.04% |
| 2002 FY | 157.36 Thousand USD | -47.82% |
| 2002 Q4 | 38.29 Thousand USD | 62.9% |
| 2002 Q3 | 23.5 Thousand USD | -55.25% |
| 2002 Q1 | 43.04 Thousand USD | -62.75% |
| 2001 Q2 | 56.46 Thousand USD | -32.04% |
| 2001 Q1 | 83.08 Thousand USD | -8.54% |
| 2001 Q4 | 115.54 Thousand USD | 148.52% |
| 2001 FY | 301.59 Thousand USD | -5.37% |
| 2001 Q3 | 46.49 Thousand USD | -17.65% |
| 2000 Q4 | 90.84 Thousand USD | -5.36% |
| 2000 Q3 | 95.99 Thousand USD | 39.93% |
| 2000 Q2 | 68.6 Thousand USD | 8.41% |
| 2000 Q1 | 63.28 Thousand USD | 0.0% |
| 2000 FY | 318.71 Thousand USD | 58.1% |
| 1999 FY | 201.59 Thousand USD | 1.93% |
| 1998 FY | 197.78 Thousand USD | 9.65% |
| 1997 FY | 180.37 Thousand USD | -16.3% |
| 1996 FY | 215.51 Thousand USD | -3.58% |
| 1995 FY | 223.51 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -557.408% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -74.121% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 70.293% |
| Nascent Biotech, Inc. | 2.22 Million USD | -293.709% |
| Rebus Holdings, Inc. | 664 Thousand USD | -1222.174% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 76.435% |
| Qrons Inc. | 643.67 Thousand USD | -1263.919% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -2153.593% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 84.716% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -2013.039% |
| Skye Bioscience, Inc. | 13.54 Million USD | 35.197% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 89.884% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -78.515% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -3254.361% |
| SQZ Biotechnologies Company | 85.61 Million USD | 89.746% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -201.047% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -484.542% |
| Mesoblast Limited | 5.9 Million USD | -48.75% |
| Marizyme, Inc. | 19.23 Million USD | 54.369% |
| Genus plc | 147.7 Million USD | 94.056% |
| Pharming Group N.V. | 225.49 Million USD | 96.107% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -328.526% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -554.412% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -5.279% |
| ContraFect Corporation | 56.88 Million USD | 84.568% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -99.136% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -493.692% |
| IMV Inc. | 37.7 Million USD | 76.719% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -214.628% |
| MultiCell Technologies, Inc. | 567.42 USD | -1547119.696% |
| ONE Bio Corp. | 6.44 Million USD | -36.241% |
| Accustem Sciences Inc. | 3.74 Million USD | -134.337% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 89.785% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -1550.35% |
| Q BioMed Inc. | 3.43 Million USD | -155.461% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 64.478% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -234.126% |
| Biomind Labs Inc. | 994.18 Thousand USD | -783.061% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 91.162% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -398.911% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -30.682% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -370.895% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 35216.936% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 45.165% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -378.408% |
| GB Sciences, Inc. | 1.42 Million USD | -518.034% |
| Alpha Cognition Inc. | 9.7 Million USD | 9.545% |
| HST Global, Inc. | 140.9 Thousand USD | -6130.517% |
| CSL Limited | 3.44 Billion USD | 99.745% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -680.439% |
| Halberd Corporation | 74.84 Thousand USD | -11630.357% |
| Enzolytics Inc. | 2.17 Million USD | -302.808% |
| Agentix Corp. | 1.37 Million USD | -540.0% |
| Resverlogix Corp. | 12.71 Million USD | 30.937% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -140.48% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.428% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -740.923% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -265.051% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -455.875% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -157.835% |
| AVAX Technologies, Inc. | 7.31 Million USD | -20.095% |
| Zenith Capital Corp. | 8.94 Million USD | 1.831% |
| Genscript Biotech Corporation | 825.34 Million USD | 98.936% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -50294.547% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -257.56% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -5018.818% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -357.036% |
| Kadimastem Ltd | 2.41 Million USD | -264.267% |
| Helix BioMedix, Inc. | 1.97 Million USD | -345.187% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 19.212% |
| BioStem Technologies, Inc. | 22.97 Million USD | 61.788% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -4737.443% |
| LadRx Corporation | 3.81 Million USD | -130.318% |
| Cell Source, Inc. | 4.32 Million USD | -102.972% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -850.638% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -850.638% |
| NovAccess Global Inc. | 2.46 Million USD | -255.901% |
| Affymax, Inc. | 39.38 Million USD | 77.71% |
| Itoco Inc. | 919.14 Thousand USD | -855.154% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -107.135% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -684.561% |
| Mobile Lads Corp. | 554.54 Thousand USD | -1483.139% |
| CytoDyn Inc. | 18.05 Million USD | 51.383% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -34781.139% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -3889.147% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -518.346% |
| SYBLEU INC | 160.87 Thousand USD | -5357.143% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -383.353% |
| International Stem Cell Corporation | 5.27 Million USD | -66.557% |
| Bioxytran, Inc. | 3.82 Million USD | -129.814% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -16577.243% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -43056.044% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 75.792% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -442.598% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -1093.098% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -182.2% |
| Neutra Corp. | 243.82 Thousand USD | -3500.688% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 49.709% |
| PureTech Health plc | 144.59 Million USD | 93.928% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 57.153% |
| IXICO plc | 4.7 Million USD | -86.514% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 0.202% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 92.544% |
| CSL Limited | 3.89 Billion USD | 99.774% |
| Cellectis S.A. | 97.32 Million USD | 90.979% |